Merck & Co: Intismeran Plus Keytruda Significantly Reduced The Risk Of Recurrence Or Death By 42% Vs Keytruda Alone

Safety Profile Was Generally Consistent With Previously Reported Studies Of Combination - Reduced Risk Of Recurrence Or Death By 58% Compared To Keytruda Alone - In Phase 3 Interpath-001 Trial, No New Safety Signals Were Observed